从血液和骨髓移植的证据到临床实践。
From evidence to clinical practice in blood and marrow transplantation.
作者信息
Khera Nandita
机构信息
College of Medicine, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA.
出版信息
Blood Rev. 2015 Nov;29(6):351-7. doi: 10.1016/j.blre.2015.04.001. Epub 2015 Apr 19.
Abstract
Clinical practice in the field of blood and marrow transplantation (BMT) has evolved over time, as a result of thousands of basic and clinical research studies. While it appears that scientific discovery and adaptive clinical research may be well integrated in case of BMT, there is lack of sufficient literature to definitively understand the process of translation of evidence to practice and if it may be selective . In this review, examples from BMT and other areas of medicine are used to highlight the state of and potential barriers to evidence uptake. Strategies to help improve knowledge transfer are discussed and the role of existing framework provided by the Center for International Blood and Marrow Transplant Registry (CIBMTR) to monitor uptake and BMT Clinical Trials Network (BMT CTN) to enhance translation of evidence into practice is highlighted.
摘要
由于数千项基础和临床研究，血液与骨髓移植（BMT）领域的临床实践随着时间的推移而不断发展。虽然在BMT领域，科学发现与适应性临床研究似乎得到了很好的整合，但缺乏足够的文献来确切了解证据转化为实践的过程以及这一过程是否具有选择性。在本综述中，我们使用了BMT和其他医学领域的例子来突出证据采纳的现状和潜在障碍。我们讨论了有助于改善知识转移的策略，并强调了国际血液与骨髓移植登记中心（CIBMTR）提供的现有框架在监测采纳情况方面的作用，以及骨髓移植临床试验网络（BMT CTN）在促进证据转化为实践方面的作用。
相似文献
1
From evidence to clinical practice in blood and marrow transplantation.从血液和骨髓移植的证据到临床实践。
Blood Rev. 2015 Nov;29(6):351-7. doi: 10.1016/j.blre.2015.04.001. Epub 2015 Apr 19.
2
Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization.临床研究向实践的转化：对血液和骨髓移植临床试验网络方案 0201 对非亲缘供者移植源利用结果的影响评估。
Biol Blood Marrow Transplant. 2018 Nov;24(11):2204-2210. doi: 10.1016/j.bbmt.2018.06.028. Epub 2018 Jun 30.
3
Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.在异基因移植中，与疾病或治疗相关的骨髓损伤无法通过改变干细胞来源或剂量来克服。
Eur J Haematol. 2004 Jul;73(1):1-9. doi: 10.1111/j.1600-0609.2004.00255.x.
4
Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report From the BMT CTN Patient and Caregiver Advocacy Task Force.将患者和照护者的声音纳入临床试验合唱团：来自 BMT CTN 患者和照护者倡导工作组的报告。
Transplant Cell Ther. 2023 Jan;29(1):5-9. doi: 10.1016/j.jtct.2022.10.016. Epub 2022 Oct 23.
5
Blood and marrow transplant clinical trials network (BMT CTN): addressing unanswered questions.血液与骨髓移植临床试验网络（BMT CTN）：解决未解答的问题。
Biol Blood Marrow Transplant. 2007 Mar;13(3):257-62; discussion 255-6. doi: 10.1016/j.bbmt.2006.11.017.
6
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.血液与骨髓移植临床试验网络：解决造血细胞移植重要问题的有效基础设施。
Biol Blood Marrow Transplant. 2016 Oct;22(10):1747-1757. doi: 10.1016/j.bbmt.2016.07.003. Epub 2016 Jul 11.
7
Haploidentical stem cell transplantation-bone marrow vs peripheral blood.单倍体相合干细胞移植——骨髓与外周血
Transfus Apher Sci. 2018 Apr;57(2):168-170. doi: 10.1016/j.transci.2018.04.015. Epub 2018 Apr 19.
8
The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research.登记处在促进骨髓移植临床研究中的作用：来自国际血液和骨髓移植研究中心的实例
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S1-S2. doi: 10.1038/bmt.2008.101.
9
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.成人血液系统恶性肿瘤的骨髓与外周血异基因造血干细胞移植
Cochrane Database Syst Rev. 2014 Apr 20;2014(4):CD010189. doi: 10.1002/14651858.CD010189.pub2.
10
Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007.血液和骨髓移植临床研究网络：自 2007 年科学研讨会以来的进展。
Biol Blood Marrow Transplant. 2014 Feb;20(2):149-53. doi: 10.1016/j.bbmt.2013.11.006. Epub 2013 Nov 12.
引用本文的文献
1
Applying Implementation Science in the Field of Transplant and Cellular Therapy.在移植和细胞治疗领域应用实施科学。
Transplant Cell Ther. 2024 Sep;30(9):864-875. doi: 10.1016/j.jtct.2024.06.018. Epub 2024 Jun 21.
2
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?我们如何将新证据更好地转化到造血细胞移植和细胞治疗的实践中？
Blood Rev. 2023 Jul;60:101079. doi: 10.1016/j.blre.2023.101079. Epub 2023 Apr 7.
3
Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee.造血细胞移植和细胞治疗的系统评价：美国移植和细胞治疗学会、欧洲血液和骨髓移植学会以及国际血液和骨髓移植研究中心晚期效应和生活质量工作组的考虑因素和指导意见。
Transplant Cell Ther. 2021 May;27(5):380-388. doi: 10.1016/j.jtct.2020.12.002. Epub 2021 Jan 28.
4
Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee.造血细胞移植和细胞治疗的系统评价：美国移植和细胞治疗学会、欧洲血液和骨髓移植学会以及国际血液和骨髓移植研究中心晚期效应和生活质量工作组的考虑因素和指导意见。
Bone Marrow Transplant. 2021 Apr;56(4):786-797. doi: 10.1038/s41409-020-01199-1. Epub 2021 Jan 29.
5
A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703.移植物抗宿主病预防的新标准？血液和骨髓移植临床研究网络 1703 简介。
Biol Blood Marrow Transplant. 2020 Dec;26(12):e305-e308. doi: 10.1016/j.bbmt.2020.08.029. Epub 2020 Sep 10.
本文引用的文献
1
Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).试验结果对患有晚期实体瘤的老年医疗保险患者的可推广性（联盟70802）。
J Natl Cancer Inst. 2014 Nov 27;107(1):336. doi: 10.1093/jnci/dju336. Print 2015 Jan.
2
One-unit versus two-unit cord-blood transplantation for hematologic cancers.单份脐带血与双份脐带血移植治疗血液系统恶性肿瘤的比较
N Engl J Med. 2014 Oct 30;371(18):1685-94. doi: 10.1056/NEJMoa1405584.
3
External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer.试验中纳入了激素受体阳性的老年乳腺癌患者，其外部有效性。
J Natl Cancer Inst. 2014 Apr;106(4):dju051. doi: 10.1093/jnci/dju051. Epub 2014 Mar 19.
4
Comparison of survival outcomes among cancer patients treated in and out of clinical trials.比较临床试验内外治疗的癌症患者的生存结果。
J Natl Cancer Inst. 2014 Mar;106(3):dju002. doi: 10.1093/jnci/dju002. Epub 2014 Mar 13.
5
Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation.质量管理体系“JACIE”的应用与造血干细胞移植后的结果
Haematologica. 2014 May;99(5):908-15. doi: 10.3324/haematol.2013.096461. Epub 2014 Jan 31.
6
Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients.老年患者复杂抗血栓治疗的下消化道和上消化道出血、输血和住院风险。
Circulation. 2013 Oct 22;128(17):1869-77. doi: 10.1161/CIRCULATIONAHA.113.004747. Epub 2013 Sep 11.
7
Peripheral-blood stem cells versus bone marrow from unrelated donors.外周血造血干细胞与无关供者骨髓。
N Engl J Med. 2012 Oct 18;367(16):1487-96. doi: 10.1056/NEJMoa1203517.
8
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.来那度胺维持治疗多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.
9
Lenalidomide after stem-cell transplantation for multiple myeloma.来那度胺用于多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083.
10
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.自体造血干细胞移植继以异基因或自体造血干细胞移植治疗多发性骨髓瘤患者（BMT CTN 0102）：一项 3 期生物学任务试验。
Lancet Oncol. 2011 Dec;12(13):1195-203. doi: 10.1016/S1470-2045(11)70243-1. Epub 2011 Sep 29.
Zotero 插件